INNOVATION WITH INTEGRITY

Bruker Corporation (Nasdaq: BRKR) 2023 JP Morgan Healthcare Conference

Frank H. Laukien

Chairman, President & CEO

Bruker Corporation

January 9, 2023

Safe Harbor Statement

Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our preliminary fourth quarter and fiscal year ended December 31, 2022 operational and financial performance, including our revenue growth, non-GAAP operating margin, non-GAAP EPS and non-GAAP tax rate; ROIC; EBITDA; management's expectations for future financial and operational performance, expected growth, and business outlook; statements regarding our business focus, expected market growth and market size; and product performance. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to the length and severity of the COVID-19 pandemic, the impact of the pandemic on global economic conditions, the impact of any supply chain disruptions, continued volatility in the capital markets, the impact of Project Accelerate, the performance of breakout opportunities, the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, fluctuations in foreign currency exchange rates and their impact, our ability to successfully implement our restructuring initiatives and other cost reduction initiatives, changing technologies, product development and market demand and acceptance of our products, the success of our R&D investment initiatives, the cost and pricing of our products, manufacturing, competition, loss of key personnel, dependence on collaborative partners, key suppliers and contract manufacturers, capital expenditures, debt levels, payment of dividends, government funding policies, changes in governmental regulations, the use and protection of intellectual property rights, litigation, and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2021, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

YTD Q3 2022: Robust Organic Growth with Solid Margin Expansion

Solid Q4 2022 Organic Revenue Growth, Strong 2023 Outlook

YTD Q3 2022 Financials (all year-over-year)

- Revenue increased $87.9M, up +5.1%
  - **Organic revenue growth +10.7%** (BSI +9.9%, BEST +18.7%); acquisitions tailwind +1.3%, FX headwind -6.9%
- **Non-GAAP gross margin 52.6%, up +160 bps**
- **Non-GAAP operating margin 19.6%, up +80 bps**
  - Continuing significant investments in PA 2.0 R&D, M&S opex
- Non-GAAP EPS of $1.60, up 6%





Q4 2022 Preliminary Revenue Estimate and FY 2023 Outlook(1)

- Q4-22 preliminary revenue estimate**: mid-to-high single digit % organic growth YoY[2];** reported revenue above consensus
  - Solid demand, with Q4-22 **BSI book-to-bill expected at >1**
  - **BSI backlog remains high** due to supply chain constraints
- Preliminary 2023 outlook**: mid-to-high single digit % organic revenue growth YoY**
  - *Project Accelerate 2.0* initiatives performing well, **Proteomics and Spatial Biology accelerating** organically and inorganically

BSI Geographic Mix (YTD 3Q 2022 revenue)



(1) Please see disclosures on slide 21 (2) Q4-22 preliminary: GAAP revenue up low single digits % YoY: organic revenue up mid-to-high single digit %, ~7% headwind from FX, ~1.5% tailwind from acquisitions.

DUAL STRATEGY

High-Value Innovation for Strong Revenue and Non-GAAP EPS Growth, with Continued Sustainable Margin Improvements

Project Accelerate 2.0

- High Value Innovation & fast revenue and EPS growth
- Continued margin expansion
- Expanded, very large TAMs
- At inflection of expected large opportunities in **Proteomics** and **Spatial Biology**

Operational Excellence

- Excellence in operations & logistics
- Commercial excellence
- Product R&D excellence
- Expanding gross margins
- High ROIC philosophy
- Major environmental investments for sustainability

- We build through innovation and disciplined entrepreneurialism, e.g., in Microbiology, BioPharma, Phenomics, Semi Metrology
- We enable and pursue potential breakout opportunities in Proteomics and Spatial & Cell Biology
- We manage our core businesses for profitable growth, high ROIC and long-term, sustainable stakeholder success
- Developing new high-growth, high-margin opportunities in Cancer research, Neuroscience research and Cleantech tools.

Proprietary *TimsTOF®* Mass Spec Platform Enables *4D Proteomics™ Revolution*

Global timsTOF installed base end of 2022 at >600 units



Research Highlight #1:
timsTOF enabling in-depth mapping of human brain proteome

- **Dr. Bernard Kuster's lab at Technical University Munich (TUM)** utilizing **timsTOF HT** for in-depth mapping of human brain proteome
- **Leading-edge speed & robustness:**
  - **>2,000 tissue samples using robust 50 µL/min flow rates**
  - **Avg. >3,000 PGs with 30-minute gradients from FFPE brain tissue**
  - **In total >9,000 protein groups identified from 13 brain regions**

Bruker's VIP HESI source at 50 µL/min

Prof. Dr. Bernhard Küster

"The speed and robustness of the timsTOF HT with our innovative higher flow rates combine to allow our lab to think about projects involving large sample cohorts that simply would have taken too long with previous generations of mass spectrometers."

Research Highlight #2:
timsTOF in large-scale plasma proteomics study of COVID-19

- **Drs. Hanno and Judith Steen at Children's Hospital, Boston,** utilized the **timsTOF Pro** for plasma proteomics on 4,570 samples from 1,000 patients
  - Resulting in most complete plasma proteome library to date
  - Novel sample-preparation and bioinformatic workflows
  - Combined with leading capabilities of **timsTOF** with **dia-PASEF**, can now be applied to future, large-scale plasma proteomics studies



Professors Hanno and Judith Steen

"The TIMSTOF platform was critical to our lab completing a demanding study of thousands of samples in plasma, something that until now was unachievable by MS methods. Now we actively look for larger sample cohorts because we know we have the capabilities."

Dr. Hanno Steen, Associate Professor of Pathology, Harvard Medical School and PI, Children's Hospital

Research Highlight #3:
timsTOF enabling higher throughput single-cell proteomics

- **timsTOF SCP (Single Cell Proteomics)** has a robust workflow and very high sensitivity, with **>3,500 proteins** identified on average in single cells
- Professor Nikolai Slavov at Northeastern University is pioneering ***plexDIA*** to combine sensitivity of Data Independent Analysis (DIA) with throughput of labeling to **quantify > 1,000 protein groups per cell with only 5 min nanoLC gradients on timsTOF SCP**

Prof. Nikolai Slavov



Expanding Portfolio for Spatial Biology & Single-Cell Omics: *Canopy CellScape™* and *MALDI HiPLEX-IHC™*



CellScape™ spatial single-cell proteomics

- Highly multiplexed spatial omics with walk-away automation
- Best-in-class 0.2 µm resolution
- Proprietary high dynamic range (HDR) for excellent quantitation
- Rapid analysis of whole tissue sections with larger FOVs
- Primary monoclonal antibodies for high specificity



MALDI HiPLEX-IHC™ spatial tissue multiomics

- Miralys™ antibody-based photocleavable peptide mass tags for very high targeted proteomics multiplexing (>100x feasible)
- Breakthrough in spatial multiomics, combining protein expression with unbiased small molecule imaging
- Co-localize proteins, glycans, lipids, and metabolites

Canopy *CellScape*™ ChipCytometry

Differentiated Quantitative Performance for Spatial Single-Cell Proteomics

Highest Optical Resolution

True single cell resolution

Best-in-class optical resolution

182 nm/pixel



High Dynamic Range

Quantitative AI



Proprietary high dynamic range (HDR) image acquisition enables detection of low and high expression

Proprietary algorithms for quantitative interpretation

High Throughput

Walk-away Automation



Rapid analysis of whole tissue sections with larger FOVs

Walk-away automation

Open-Source Antibodies

Pre-validated Panels

350+ validated antibodies



Flexibility and customization - use the clones you know

Primary monoclonal antibodies for high specificity

Demonstrated with standard RNA markers as well

Human breast carcinoma

100-plex study on Canopy CellScape™

Image on right shows FOV below.

- CD8 and CD4 illustrate T cells
- CD20 marks B cells
- CD56 shows NK cells
- pan-Cytokeratin highlights epithelial cells
- CD340(Her2) marks tumor cells.





Thoughtful M&A and Majority Investment Strategy:
Accelerate *Project Accelerate 2.0* initiatives and enhance core business

1. *Enhance and expand* life-science research solutions

2. Enter *adjacent growth markets* with strong synergies

3. *Enter attractive new markets* with strong secular tailwinds

Recent M&A focused on ***Project Accelerate 2.0,*** including our **breakout opportunities**:

Proteomics

Spatial & Cell Biology

New platforms, applications software, biocomputing, automation, consumables, chromatography, columns

New: Specialty High-value CRO Services, Focus on Neuroscience Research solutions

PREOMICS

BIOGNOSYS
NEXT GENERATION PROTEOMICS

prolab Instruments GmbH

PepSep

CANOPY BIOSCIENCES

Acuity SPATIAL GENOMICS

INSCOPIX

ACQUIFER

neurescence
BIOLOGICAL OPTICAL IMAGING

iNSCOPIX Neuroscience Research Solutions

Pioneering life brain mapping technology to directly observe neuronal ensembles and **brain circuits** during real-time behavior

New AI-driven models combine neuronal ensemble activity and behavioral data to make CNS therapeutics development more mechanistic and predictive

Strong momentum in neuroscience research market with large opportunity to apply iNSCOPIX platform in neurotherapeutic development

#1
Innovation
2021 The Scientist

Tech
Pioneer
2016 WEF

1,000+
Systems Worldwide

600+
Sites Worldwide

200+
Publications With Inscopix

6
Nobel Laureates on Inscopix

~$20M
FY2022 revenues

>60%
Gross Margins

Mapping Life Brain Circuits in Action is Key to Developing Mechanistic and Predictive Preclinical Neuroscience Models



"We can measure the activity of a single neuron, or we can look at the whole brain. But a big intermediate zone there where you want to understand entire circuits in the brain and how they function when the brain is actually doing something, that has been out of our reach. We have not had the ability to do that kind of simultaneous recording of thousands of neurons to see what they're up to."

– Dr. Francis Collins, former NIH Director

Inscopix Platform as an Integrated Neuroscience Research Solution

Mesoscale Life Brain-Mapping Platform

Ready-to-Image Virus

Proview™ Integrated Lens



Proview™ Express Probe



Data Acquisition

nVue™ System for Dual Color Imaging

Data Processing



Inscopix Data Processing Software

Validated Applications and Comprehensive Support to Enable Success


BRUKER
BIOGNOSYS
NEXT GENERATION PROTEOMICS
Transformative insights from discovery to clinic

Biognosys Makes Proteome Accessible by Covering Needs of a Wide Range of Biomarker and Biopharma Researchers

Bruker acquired >80% of Biognosys in January 2023. Biognosys 2022 revenues ~$15M.
We expect DD growth, strong synergies, accretive to EBIT in 3 years, double-digit ROIC in 5 years.

Mission By inventing and providing next-generation proteomics solutions Biognosys gives disease researchers and drug hunters a look at every angle of the proteome to unlock true discoveries and transform clinical research and decision making.

Premier Proteomics CRO Services

End-to-end Basic Research and Clinical Trial Solutions

TRUE SIGNATURE™
CUSTOM PANELS FOR ABSOLUTE PROTEIN QUANTIFICATION

TRUE TARGET™
NOVEL DRUG TARGET IDENTIFICATION AND VALIDATION

State-of-the-art high-throughput, automated proteomics facility in Switzerland.
Bruker investments pending for 2nd Biognosys proteomics CRO facility in the US, also for pharmacoproteomics and clinical trial support.

Proteomics Software

DIA Spectronaut™ powered by Pulsar

Targeted SpectroDive™ powered by Pulsar

DDA, ILQ SpectroMine™ powered by Pulsar

Quality Control QuiC™ powered by Pulsar

AI-empowered software for streamlined data analytics

Proteomics Kits

Absolute Quantification
PQ500™

Quality Control
iRT Kit

Sample Preparation
SP Kit Pro

Biognosys By The Numbers

> 14 Years of Proteomics Innovation

> 50% PhD Scientists, ~80 employees

58 Granted International Patents

> 2000 Publications mentioning our Technology

nature | nature methods | Cell | MCP MOLECULAR & CELLULAR PROTEOMICS

> 900 m^2 Lab & Instruments Facility

> 800 Clients

~$15m revenue p.a.

US Offices in Cambridge, MA

Co-founded by **proteomics pioneer Ruedi Aebersold** (ETH Zurich)

Strong **scientific foundation** and **R&D-centric** mindset

Inventor and developer of unique, proprietary proteomics solutions

Co-authored multiple publications in **high-impact, peer-reviewed journals**

One of the largest facilities in the world for **high-res discovery proteomics**

Diverse clients for products and CRO services in global customer base

PROJECT ACCELERATE 2.0 DELIVERS

Faster Growth from Six High-Growth, High-Margin Initiatives & Operational Excellence

Consumables, Scientific Software & Aftermarket

Consumables, assays, services, libraries & scientific software

Next-gen Nanomaterials Research & Semi Metrology

Enabling R&D and QC of next-gen logic, memory, displays, renewable energy, nanotools and nanomaterials

Spatial Biology, Single-Cell Omics, and Cellular Analysis

Super-resolution microscopy & cytometry for immunology, oncology, single-cell and subcellular spatial biology and targeted multiomics;
Acuity Spatial 3D Genomics

Unbiased 4D-Proteomics & Epiproteomics, *Functional* Structural Biology, SCP

Proteomics, PTMs, multiomic LBx, tissue SpatialOMx, *functional* structural biology, biomolecular condensates, unbiased single-cell proteomics

Biopharma & Applied

High-value NMR, MS and FTIR/NIR solutions for drug discovery, development and pharma PAT; Applied food analysis and forensics

Microbiology & Molecular Dx

High-value solutions for faster, accurate and broadly scalable infectious disease diagnostics, including viral MDx

Appendix

Disclosures about Q4 2022 and 2023 commentary on slide 3

- *Reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is available at the end of this presentation.*
- *Because the Company's financial statements for the fiscal year ended December 31, 2022 have not yet been finalized or audited, the preliminary statements regarding the Company's expectations regarding its fiscal year 2022 revenue are subject to change, and the Company's actual revenue growth for this period may differ materially from this preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate.*

Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)

(in millions, except per share amounts)	Twelve Months Ended December 31,					Three Months Ended December 31,	Nine Months Ended September 30,	Last Twelve Months Ended September 30,
	2017 [1]	2018	2019	2020	2021	2021	2022	2022
Revenue	$ 1,765.9	$ 1,895.6	$ 2,072.6	$ 1,987.5	$ 2,417.9	$ 683.5	$ 1,822.3	$ 2,505.8
Reconciliation of Non-GAAP Operating Income, Non-GAAP Profit Before Tax, Non-GAAP Net Income, and Non-GAAP EPS								
GAAP Operating Income	$ 219.5	$ 262.4	$ 300.9	$ 248.3	$ 413.3	$ 125.4	$ 301.7	$ 427.1
Non-GAAP Adjustments:								
Restructuring Costs	16.2	9.4	1.4	15.8	8.2	3.0	4.4	7.4
Acquisition-Related Costs	10.2	7.3	16.8	3.2	6.9	3.0	15.4	18.4
Purchased Intangible Amortization	29.6	28.9	38.3	35.7	37.4	10.2	27.5	37.7
Other Costs	5.4	9.9	6.6	14.2	4.4	2.2	7.7	9.9
Total Non-GAAP Adjustments:	$ 61.4	$ 55.5	$ 63.1	$ 68.9	$ 56.9	$ 18.4	$ 55.0	$ 73.4
Non-GAAP Operating Income	$ 280.9	$ 317.9	$ 364.0	$ 317.2	$ 470.2	$ 143.8	$ 356.7	$ 500.5
Non-GAAP Operating Margin	*15.9%*	*16.8%*	*17.6%*	*16.0%*	*19.4%*	*21.0%*	*19.6%*	*20.0%*
Non-GAAP Interest & Other Expense, net	(22.3)	(17.7)	(20.5)	(22.5)	(19.7)	(5.9)	(10.4)	(16.3)
Non-GAAP Profit Before Tax	258.6	300.2	343.5	294.7	450.5	137.9	346.3	484.2
Non-GAAP Income Tax Provision	(64.7)	(78.5)	(96.6)	(82.9)	(126.1)	(47.4)	(105.8)	(153.2)
Non-GAAP Tax Rate	*25.0%*	*26.1%*	*28.1%*	*28.1%*	*28.0%*	*34.4%*	*30.6%*	*31.6%*
Minority Interest	(1.7)	(1.3)	(0.8)	(3.6)	(3.5)	(0.3)	(1.0)	(1.3)
Non-GAAP Net Income Attributable to Bruker	192.2	220.4	246.1	208.2	320.9	90.2	239.5	329.7
Weighted Average Shares Outstanding (Diluted)	159.1	157.2	156.6	154.6	152.9	152.5	149.9	
Non-GAAP Earnings Per Share	$ 1.21	$ 1.40	$ 1.57	$ 1.35	$ 2.10	$ 0.59	$ 1.60	$ 2.19

[1] The Company adopted Accounting Standards Update (ASU) 2017-07 as of January 1, 2018 under the retrospective approach. Accordingly, the 2017 income statement accounts have been restated to reflect ASU 2017-07.

Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)

(in millions, except per share amounts)	Twelve Months Ended December 31,					Three Months Ended December 31,	Nine Months Ended September 30,	Last Twelve Months Ended September 30,
	2017 [1]	2018	2019	2020	2021	2021	2022	2022
Reconciliation of GAAP and Non-GAAP Gross Profit								
GAAP Gross Profit	$ 816.0	$ 900.0	$ 995.3	$ 939.8	$ 1,209.6	$ 341.6	$ 939.8	$ 1,281.4
Non-GAAP Adjustments:								
Restructuring Costs	5.6	2.6	5.2	3.8	3.4	1.8	1.1	2.9
Acquisition-Related Costs	5.7	3.9	12.2	0.8	0.7	0.6	0.3	0.9
Purchased Intangible Amortization	24.0	21.6	23.5	19.9	20.2	5.2	13.5	18.7
Other Costs	0.8	0.6	0.8	3.7	1.1	1.0	3.1	4.1
Total Non-GAAP Adjustments:	36.1	28.7	41.7	28.2	25.4	8.6	18.0	26.6
Non-GAAP Gross Profit	$ 852.1	$ 928.7	$ 1,037.0	$ 968.0	$ 1,235.0	$ 350.2	$ 957.8	$ 1,308.0
Non-GAAP Gross Margin	*48.3%*	*49.0%*	*50.0%*	*48.7%*	*51.1%*	*51.2%*	*52.6%*	*52.2%*
Reconciliation of GAAP and Non-GAAP Selling, General and Administrative (SG&A) Expenses								
GAAP SG&A Expenses	$ 415.2	$ 444.7	$ 500.2	$ 468.6	$ 561.2	$ 153.3	$ 442.7	$ 596.0
Non-GAAP Adjustments:								
Purchased Intangible Amortization	(5.6)	(7.3)	(14.9)	(15.8)	(17.2)	(5.0)	(14.0)	(19.0)
Non-GAAP SG&A Expenses	$ 409.6	$ 437.4	$ 485.3	$ 452.8	$ 544.0	$ 148.3	$ 428.7	$ 577.0
Reconciliation of GAAP and Non-GAAP Interest & Other Income (Expense), net								
GAAP Interest & Other Income (Expense), net	$ (21.7)	$ (17.7)	$ (20.5)	$ (22.5)	$ (19.7)	$ (5.9)	$ (8.8)	$ (14.7)
Non-GAAP Adjustments:								
Bargain Purchase Gain	(0.6)	-	-	-	-	-	-	-
Strategic investments related adjustments	-	-	-	-	-	-	(1.6)	(1.6)
Non-GAAP Interest & Other Income (Expense), net	$ (22.3)	$ (17.7)	$ (20.5)	$ (22.5)	$ (19.7)	$ (5.9)	$ (10.4)	$ (16.3)

[1]The Company adopted Accounting Standards Update (ASU) 2017-07 as of January 1, 2018 under the retrospective approach. Accordingly, the 2017 income statement accounts have been restated to reflect ASU 2017-07.

Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)

(in millions, except per share amounts)	Twelve Months Ended December 31,					Three Months Ended December 31,	Nine Months Ended September 30,	Last Twelve Months Ended September 30,
	2017 [1]	2018	2019	2020	2021	2021	2022	2022
Reconciliation of GAAP and Non-GAAP Tax Rate								
GAAP Tax Rate	59.4%	26.0%	29.4%	28.5%	28.7%	36.4%	31.8%	
Non-GAAP Adjustments:								
Tax Impact of Non-GAAP Adjustments	-0.1%	-0.6%	-1.3%	-0.5%	-0.8%	-1.6%	-0.6%	
U.S. Tax Reform - Toll Charge	-27.8%	-2.7%	0.6%	-0.1%	0.0%	0.0%	0.0%	
U.S. Tax Reform - Tax Rate Change	-0.6%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	
U.S. Tax Reform - Change in APB 23	-6.5%	3.5%	0.0%	0.0%	0.0%	0.0%	0.0%	
Other Discrete Items	0.6%	-0.2%	-0.6%	0.2%	0.1%	-0.4%	-0.6%	
Total Non-GAAP Adjustments:	-34.4%	0.1%	-1.3%	-0.4%	-0.7%	-2.0%	-1.2%	
Non-GAAP Tax Rate	25.0%	26.1%	28.1%	28.1%	28.0%	34.4%	30.6%	
Reconciliation of GAAP and Non-GAAP Earnings Per Share (Diluted)								
GAAP Earnings Per Share (Diluted)	$ 0.49	$ 1.14	$ 1.26	$ 1.02	$ 1.81	$ 0.50	$ 1.33	$ 1.83
Non-GAAP Adjustments:								
Restructuring Costs	0.10	0.06	0.01	0.10	0.05	0.02	0.03	0.05
Acquisition-Related Costs	0.06	0.05	0.11	0.02	0.05	0.02	0.10	0.12
Purchased Intangible Amortization	0.19	0.18	0.24	0.23	0.24	0.06	0.18	0.24
Other Costs	0.04	0.06	0.04	0.09	0.04	0.02	0.05	0.07
Income Tax Rate Differential	0.33	(0.09)	(0.09)	(0.11)	(0.09)	(0.03)	(0.09)	(0.12)
Total Non-GAAP Adjustments:	0.72	0.26	0.31	0.33	0.29	0.09	0.27	0.36
Non-GAAP Earnings Per Share (Diluted)	$ 1.21	$ 1.40	$ 1.57	$ 1.35	$ 2.10	$ 0.59	$ 1.60	$ 2.19

[1]The Company adopted Accounting Standards Update (ASU) 2017-07 as of January 1, 2018 under the retrospective approach. Accordingly, the 2017 income statement accounts have been restated to reflect ASU 2017-07.

YTD Q3 2022 Reconciliation of GAAP to Organic Revenue Growth (Unaudited)

(in millions)	Nine Months Ended September 30, 2022
Reconciliation of GAAP Reported Revenue Growth to Organic Revenue Growth	**Total Bruker**
GAAP Revenue as of Prior Comparable Period	$ 1,734.4
Non-GAAP Adjustments:	
Acquisitions and divestitures	22.7
Organic	185.7
Currency	(120.5)
Total Non-GAAP Adjustments:	87.9
Non-GAAP Revenue	$ 1,822.3
Revenue Growth	5.1%
Organic Revenue Growth	10.7%

Reconciliation of GAAP Reported Revenue Growth to Organic Revenue Growth	**Bruker Scientific Instruments [1]**
GAAP Revenue as of Prior Comparable Period	$ 1,578.9
Non-GAAP Adjustments:	
Acquisitions and divestitures	22.7
Organic	156.6
Currency	(104.1)
Total Non-GAAP Adjustments:	75.2
Non-GAAP Revenue	$ 1,654.1
Revenue Growth	4.8%
Organic Revenue Growth	9.9%

Reconciliation of GAAP Reported Revenue Growth to Organic Revenue Growth	**BEST, net of Intercompany Eliminations**
GAAP Revenue as of Prior Comparable Period	$ 155.5
Non-GAAP Adjustments:	
Organic	29.1
Currency	(16.4)
Total Non-GAAP Adjustments:	12.7
Non-GAAP Revenue	$ 168.2
Revenue Growth	8.2%
Organic Revenue Growth	18.7%

[1] Bruker Scientific Instruments (BSI) revenue reflects the sum of the BSI Life Science and BSI Nano Segments as presented in our 2021 Form 10-K.


BRUKER